Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

NCT01212601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2012-11-27

No results posted yet for this study

Summary

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Conditions

  • S. Aureus Bloodstream Infection

Sponsors & Collaborators

Principal Investigators

  • Aixia Wang, Prof. · Peiking Union Medical College Hospital

  • Karen Atkin · AstraZeneca

  • Mentha Wang · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01212601 on ClinicalTrials.gov